A key bibliometric insight is that research on CAR-NK cells emphasizes their favorable safety profile, including reduced risks of graft-vs.-host disease and cytokine release syndrome and their ability to target tumors independent of MHC restriction [146–148]. This evidence concerns the gene HLA-C and glycogen storage disease VI.